Adhd meds
Pro Research Analysisby 
Searched over 200M research papers for "adhd meds"
ADHD Medications: Efficacy and Safety in Children and Adolescents
Introduction to ADHD Medications
Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. It affects approximately 5% of children and adolescents globally. The primary pharmacological treatments for ADHD include stimulant medications such as methylphenidate and amphetamines, and non-stimulant medications like atomoxetine, clonidine, and guanfacine .
Methylphenidate: Efficacy and Safety
Efficacy of Methylphenidate
Methylphenidate is the most commonly prescribed stimulant for ADHD. Studies indicate that it may improve teacher-rated ADHD symptoms and general behavior in children and adolescents. Specifically, methylphenidate has shown a standardized mean difference (SMD) of -0.74 in improving ADHD symptoms, which translates to a mean difference of -10.58 points on the ADHD Rating Scale . However, the certainty of this evidence is very low due to high risks of bias in the studies.
Safety of Methylphenidate
Methylphenidate is associated with several non-serious adverse events, including sleep problems and decreased appetite. The risk ratio (RR) for non-serious adverse events is 1.23, indicating a 23% higher risk compared to placebo or no intervention . Serious adverse events are not significantly affected by methylphenidate use, but the overall certainty of this evidence remains very low .
Amphetamines: Efficacy and Safety
Efficacy of Amphetamines
Amphetamines, including dexamphetamine, lisdexamphetamine, and mixed amphetamine salts, are also widely used for ADHD treatment. These medications have shown efficacy in reducing core ADHD symptoms based on parent, teacher, and clinician ratings. For instance, amphetamines have an SMD of -0.57 for parent ratings and -0.55 for teacher ratings, indicating moderate improvements in symptom severity . However, the quality of this evidence is low to very low due to high risks of bias and short study durations.
Safety of Amphetamines
Amphetamines are associated with several adverse events, including decreased appetite, insomnia, and abdominal pain. The risk ratios for these adverse events are significantly higher compared to placebo, with decreased appetite having an RR of 6.31 and insomnia an RR of 3.80 . Additionally, amphetamines may cause cardiovascular effects such as increased blood pressure and heart rate, which necessitates careful monitoring.
Non-Stimulant Medications: Efficacy and Safety
Atomoxetine, Clonidine, and Guanfacine
Non-stimulant medications like atomoxetine, clonidine, and guanfacine are alternatives for children who do not respond well to stimulants. Atomoxetine has shown efficacy in reducing ADHD symptoms but is also associated with adverse events such as increased blood pressure and heart rate . Clonidine and guanfacine, which are alpha2-adrenergic agonists, are generally well-tolerated but can cause somnolence and fatigue .
Cardiovascular and Psychiatric Concerns
Cardiovascular Effects
Both stimulant and non-stimulant medications for ADHD can have cardiovascular effects. Methylphenidate, amphetamines, and atomoxetine have been associated with small but statistically significant increases in systolic and diastolic blood pressure and heart rate. These effects are generally mild but can be clinically significant for some individuals, necessitating regular cardiovascular monitoring.
Psychiatric Concerns
There are concerns about the psychiatric effects of ADHD medications, including the risk of substance use disorders and suicidal ideation. However, current evidence does not strongly support a significant association between ADHD medications and these psychiatric adverse events .
Conclusion
ADHD medications, including methylphenidate, amphetamines, and non-stimulants like atomoxetine, clonidine, and guanfacine, are effective in managing ADHD symptoms in children and adolescents. However, they are associated with various adverse events, particularly non-serious ones like sleep problems and decreased appetite. Cardiovascular and psychiatric effects are also concerns that require careful monitoring. Despite these issues, the overall efficacy and safety profiles of these medications make them valuable options for treating ADHD, although further research is needed to improve treatment strategies and develop new medications.
Sources and full results
Most relevant research papers on this topic